| Document |
Document Title |
|
WO/2023/193114A1 |
Disclosed are methods of treating a cancer in a subject using an ATR inhibitor wherein the cancer has been previously identified as a cancer having a loss of function of STAG2, SETD2, CDK12, ATRIP, REV3L, RAD17, CHTF8, FZR1, RAD51B, RAD5...
|
|
WO/2023/195530A1 |
The present invention provides a compound showing coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. A compound represented by formula (I) [in...
|
|
WO/2023/193759A1 |
Described herein are HPK1inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with HPK1.
|
|
WO/2023/196875A1 |
The present disclosure relates generally to compounds, of Formula I: Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or...
|
|
WO/2023/193775A1 |
An organic electronic material comprising phenanthrene and phenanthroline, and an application thereof. The specific structural formula is as represented by the following formula I, . In formula I, at least one of R1 and R2 is one of subs...
|
|
WO/2023/196409A1 |
The disclosure relates to compounds that act as inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cance...
|
|
WO/2023/193790A1 |
The present invention relates to crystalline forms of an inhibitor of menin/mixed lineage leukemia (MLL) protein-protein interaction. The present invention also relates to pharmaceutical compositions comprising crystalline forms of an in...
|
|
WO/2023/195529A1 |
The present invention provides: a compound that exhibits a coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the same. The compound is represented by f...
|
|
WO/2023/196283A1 |
The present disclosure provides a compound represented by structural formula (A) or (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2023/195773A1 |
The present invention relates to a heteroaryl derivative and use thereof. The heteroaryl derivative represented by chemical formula (I) and a pharmaceutical composition including same effectively suppress HER2 activity, and thus are usef...
|
|
WO/2023/194870A1 |
The present invention relates to an improved process for the preparation of palbociclib. The present invention also relates to a novel crystalline Form G of tert-butyl 4-(6-{[6- (1-butoxyethenyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydrop...
|
|
WO/2023/195018A1 |
Solid dispersions of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8- (morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5
,6]pyrido[4,3-d]pyrimidin-2- one. The present invention relates to solid dispersions of 3-(2,6-difluoro-3,5...
|
|
WO/2023/193054A1 |
The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or prodrug thereof: Formula (I) in which R4 is 5-membered cycloalkene or 5-membered heteroaryl, each of which is optionally fused to form a ...
|
|
WO/2023/195027A1 |
The present invention relates to a process for the preparation of 4-((6bR,10aS)-3- methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrr
olo[1,2,3-de]quinoxalin-8-yl)- 1-(4-fluoro-phenyl)-butan-1-one represented by the following s...
|
|
WO/2023/192960A1 |
Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6.
|
|
WO/2023/186126A1 |
The present invention relates to an aromatic ring compound and use thereof. Specifically provided is a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable sal...
|
|
WO/2023/190224A1 |
A first problem to be addressed by the present invention is to provide a photoelectric conversion element which has excellent production adequacy. A second problem to be addressed by the present invention is to provide an imaging element...
|
|
WO/2023/187391A1 |
The present invention relates to compounds of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, (Ia) wherein: ring A is a 5- or 6-membered monocyclic aromatic or heteroaromatic ring, or a 9- or 10-membered bicyclic ...
|
|
WO/2023/185831A1 |
The present application relates to a compound containing a thiazole ring, and specifically to a compound of formula I, a preparation method therefor, a pharmaceutical composition comprising same, and use thereof in treating diseases such...
|
|
WO/2023/184327A1 |
Provided herein are novel compounds, for example, compounds having a Formula I, Formula II-1 to II-7, Formula III-1 to III-9, IV, or V, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the comp...
|
|
WO/2023/192390A1 |
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodru...
|
|
WO/2023/190663A1 |
The present invention provides an effective production method and/or purification method for a high-yield and high-purity (R)-11-[[-[(diethylamino)methyl]-1-piperidinyl]-acetyl]-5,11
-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine-6-one or ...
|
|
WO/2023/186060A1 |
Provided herein are novel compounds, for example, compounds having a structure according to Formula III-1 to III-12, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods o...
|
|
WO/2023/187182A1 |
The present disclosure relates to a compound of formula (I) wherein R1 represents a hydrogen atom, a -(C1-C6)alkyl group optionally substituted; R2 represents a hydrogen atom, a halogen atom, a -(C1-C6)alkyl group, a -(C3-C7)cycloalkyl g...
|
|
WO/2023/192416A1 |
The disclosure is directed to compounds of Formula I (I) Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
|
|
WO/2023/185811A1 |
The present invention relates to a novel heterocyclic compound; specifically, provided in the present invention are a compound represented by formula (I) or pharmaceutically acceptable salts, solvates, polymorphs or isomers thereof, a ph...
|
|
WO/2023/191201A1 |
The present invention provides a novel pyrazole derivative compound represented by chemical formula I, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomer thereof, or a pharmaceutically acceptable salt ther...
|
|
WO/2023/192817A1 |
Provided herein are compounds of Formula (I). Methods for the preparation of the compounds of Formula (I) and intermediates useful in the preparation of the compounds of Formula (I) are described herein. The compounds of Formula (I) may ...
|
|
WO/2023/192479A1 |
Disclosed embodiments concern compounds according to Formula I In some embodiments, the compounds are useful as kinase inhibitors, such as interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are compositions compris...
|
|
WO/2023/185979A1 |
Provided are a preparation method for and use of crystalline forms of an ATX inhibitor represented by formula (I) and a salt thereof. The crystalline forms of the ATX inhibitor and the salt thereof have high oral bioavailability, low hyg...
|
|
WO/2023/192801A1 |
The present disclosure provides certain sulfonamido derivatives that are Cyciin-dependent kinase 2 (CDK2) inhibitors of Formula (I): for the treatment of diseases treatable by inhibition of CDK2. Also provided are pharmaceutical composit...
|
|
WO/2023/190286A1 |
A compound represented by formula (1) or a salt thereof, or an N-oxide thereof. [In formula (1), X1 represents an oxygen atom, a sulfur atom, NY1, or C(J5J6), n represents 0 or 1, J1-J4 each represent a hydrogen atom, a halogen atom, a (...
|
|
WO/2023/190690A1 |
An electrophotographic photoreceptor comprising at least a photosensitive layer and a protective layer in sequence upon an electrically conductive support, wherein in said electrophotographic photoreceptor, the protective layer contains ...
|
|
WO/2023/187191A1 |
Compounds of the formula (I) wherein G1, G2, X, R1, R2, R3, and R4 are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compos...
|
|
WO/2023/179110A1 |
Disclosed is a method for synthesizing polyethylene polyamine under catalysis, wherein monoethanolamine and ethylenediamine are used as main raw materials, and are subjected to hydroamination under the action of a catalyst so as to obtai...
|
|
WO/2023/179196A1 |
Disclosed are a preparation and application of a Wee1 kinase inhibitor, particularly relating to a compound as shown in formula (I) or formula (II) and a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising t...
|
|
WO/2023/183275A1 |
The present disclosure relates to compound of Formula (I), such as compounds of Formula (II), (III), and (IV), useful for cGAS modulation, wherein L1, R1, R2, R9, X1, X2, X3, X4, X5, X6, X8, X9, X10, X11, Y, and r are described therein.
|
|
WO/2023/183520A1 |
Disclosed herein are inhibitors of TACC and methods of treating certain diseases and disorders (e.g., diseases and disorders related to TACC).
|
|
WO/2023/183607A1 |
Described herein are compounds or conjugates of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading c...
|
|
WO/2023/180388A1 |
The present invention provides a series of 2,4- dioxotetrahydropyrimidinyl derivatives that bind cereblon, and their application as degrons in PROTACs. Androgen receptor PROTACs containing the 2,4-dioxotetrahydropyrimidinyl containing de...
|
|
WO/2023/180964A1 |
The present invention relates to pyrazine amide derivative compounds, such as those according to formula (I) and compositions including said compounds, The invention also provides such pyrazine amide derivative compounds for use in the t...
|
|
WO/2023/179703A1 |
Provided herein are compounds having the following structure (I), wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of KRAS G12D and/or G12V.
|
|
WO/2023/179629A1 |
The present invention relates to a substituted bridged ring inhibitor, and to a preparation method therefor and application thereof. Specifically, the compound of the present invention has the structure shown in a formula (A0), and furth...
|
|
WO/2023/183540A1 |
Described herein are compounds of Formulae I' and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as IKZF2 degraders).
|
|
WO/2023/183601A1 |
This disclosure features methods for preparing tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one-containing chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that inhibit epidermal growth factor receptor (EGFR, E...
|
|
WO/2023/179542A1 |
The present disclosure relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.
|
|
WO/2023/183919A1 |
Described herein are compounds of Formula II and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as IKZF2 degraders) in treating or preventing diseases or disorders.
|
|
WO/2023/183613A2 |
The present invention discloses compounds, compositions, methods for modulating central nervous system activity, methods for treating inflammatory or metabolic disorders, and methods for treating central nervous system disorders, such as...
|
|
WO/2023/182835A1 |
The present invention relates to a novel organic compound and an organic electroluminescent element using same, and more specifically, to a compound having excellent electron injection and transport capabilities, and an organic electrolu...
|
|
WO/2023/179624A1 |
Disclosed in the present invention are a preparation method for a tricyclic compound, and an intermediate thereof, and specifically disclosed is a method for preparing a compound as shown in formula (I-10) or an optical isomer thereof. T...
|
